MILE.CA
AstraZeneca PLC
Healthcare · Drug Manufacturers - General · GB
Jul 24, 2026, 12:30 UTC
The CHMP of the European Medicines Agency recommended approval of Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer in the EU.
Source:Jul 24, 2026, 11:30 UTC
The CHMP of the EMA recommended approval of AstraZeneca's Trixeo Aerosphere for maintenance treatment of asthma in the EU.
Source:Jul 14, 2026, 16:17 UTC
Hagens Berman opened an investigation into Ionis Pharmaceuticals for potential securities law violations after a trial failure caused a 23% stock drop.
Jul 9, 2026, 11:42 UTC
AstraZeneca and Ionis Pharmaceuticals launched eplontersen sodium injection (Wainua) in China on July 8, 2026.
Source:Jul 4, 2026, 13:34 UTC
Hong Kong's Lok Ma Chau Loop Hong Kong-Shenzhen Innovation and Technology Park has attracted 90 technology companies to sign leases and move in as of end-May, with 10 being listed or leading innovation firms.
Jul 2, 2026, 01:00 UTC
Abbisko Therapeutics entered a strategic collaboration agreement with AstraZeneca to jointly advance clinical development of a novel IO-TKI combination therapy for NSCLC.
Source:Jun 29, 2026, 23:00 UTC
Texas Attorney General's Office announced a $34 million settlement with AstraZeneca Pharmaceuticals LP over allegations of an illegal kickback scheme that influenced Medicaid-covered prescriptions.
Jun 29, 2026, 14:55 UTC
AstraZeneca's Enhertu received EU approval for HER2-positive solid tumors, its sixth EU indication.
Jun 24, 2026, 13:00 UTC
AstraZeneca and YMCA of the USA announced a five-year partnership to strengthen cancer education and support programs.
Source:Jun 23, 2026, 05:30 UTC
Korea Health Industry Development Institute held partnering sessions for 13 Korean biotech companies with AstraZeneca under Project NOVA at the BIO International Convention in San Diego.
Source:Jun 16, 2026, 17:56 UTC
The FDA accepted AstraZeneca's filing for expanded use of Ultomiris to treat IgA nephropathy, granting priority review.
Source:Jun 12, 2026, 22:44 UTC
The US FDA approved AstraZeneca's TRUQAP (capivasertib) combination as a targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer.
Source:Jun 9, 2026, 13:35 UTC
AstraZeneca reported encouraging mid-stage trial results for its experimental weight-loss pill elecoglipron, showing 11.8% weight loss after 36 weeks.
Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.
← PreviousPage 3